Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
All articles by Jessica Nye, PhD
Trastuzumab Deruxtecan Elicits Responses in HER2-Low Early Breast Cancer
Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.
Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
T-DXd Improves Survival vs T-DM1 in HER2+ Advanced Breast Cancer
Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
Trastuzumab Deruxtecan Improves PFS and OS in HER2+ Advanced Breast Cancer
Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer.
DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer
Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.
Deaths on the Rise in Patients With Malignant Brain Tumors
Deaths among patients with primary malignant brain tumors are on the rise in the United States, data suggest.
Predicting Outcomes of Regorafenib in Patients With Recurrent Glioblastoma
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.
Some Patients With High-Grade Glioma Continue Using Opioids After Perioperative Period
Nearly a third of patients with high-grade glioma who were prescribed opioids after surgery continued to take them beyond the perioperative setting.
Intracranial Metastasis of Esthesioneuroblastoma May Occur 19 Years After Remission
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
- Loading...
Loading...
Next post in SNO 2022
Loading... 
Loading...